<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Citruslabs on Medium]]></title>
        <description><![CDATA[Stories by Citruslabs on Medium]]></description>
        <link>https://medium.com/@citruslabs?source=rss-55e5d328832d------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*8_qdNisr-_rYlwL7T4HH6g.png</url>
            <title>Stories by Citruslabs on Medium</title>
            <link>https://medium.com/@citruslabs?source=rss-55e5d328832d------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 07:06:02 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@citruslabs/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Challenges for Women in Research]]></title>
            <link>https://medium.com/@citruslabs/challenges-for-women-in-research-df89ec1e9eed?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/df89ec1e9eed</guid>
            <category><![CDATA[patient-recruitment]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[women]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Tue, 07 Sep 2021 18:57:59 GMT</pubDate>
            <atom:updated>2021-09-07T18:57:59.161Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*wRYSCdjMaqySVWA89C2a-w.png" /></figure><p>Women in science and technology careers often face obstacles that their male peers do not, and clinical research is no exception. A recent study revealed some of the specific challenges womenworking in research careers deal with, and what can be done to improve these conditions.</p><h3>Challenges</h3><p>According to the <a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238635"><strong>2020 study by Fathima et al.,</strong></a> while most female scientists reported some form of maternity leave at their workplace, less than a third were offered some form of workplace nursery or child care — making the return to work more expensive and stressful.</p><p>The leading challenge reported by 71.5% of women was workplace related stress. This stress is mostly induced by a lack of work-home life balance (reported by 46%.) Women frequently reported having to work beyond standard working hours, including night shifts, despite family obligations and child caring responsibilities.</p><p>Other challenges include those posed by peers, namely sexual harassment and excessive personal questions. Further, only 41% of women in science careers felt that management in their field held a positive attitude towards women’s careers progressing.</p><h3>Support</h3><p>Some of the best remedies to the described challenges are flexible work timings, woman-friendly management policies, and fair appraisal and mentorship opportunities.</p><p>Flexible work timings, woman-friendly management policies, fair appraisal and mentorship appear to reduce the work-related stress and improve work-life balance among female scientists. Very few women in science feel that the HR policies of their workplace are women-friendly, and these can be improved by<a href="https://seattlebusinessmag.com/workplace/27-best-practices-woman-friendly-workplace"><strong> implementing some of the following practices:</strong></a><strong> implementing some of the following practices:</strong></p><ol><li>Emphasize results over “seat-time”</li><li>Conduct regular compensation evaluations for employees of all levels.</li><li>Evaluate causes of attrition among women, including mothers and women who do not have children.</li><li>Actively recruit, mentor, and sponsor women into higher level executive positions.</li></ol><p>A whopping 75.7% of women knew of another woman in science who had to leave their career due to some barrier — this number is far too high, and can be prevented by listening to the actual needs of women in research and accommodating them.</p><h3>Want to Learn More?</h3><p>In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO and can help you from study startup to trial completion. With a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (and specifically study design) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.</p><p>For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.</p><p>If you’d like to hear more about what we do, go<a href="https://www.citruslabs.com/post/what-you-get-when-you-use-citruslabs-for-your-patient-recruitment"><strong> here</strong></a><strong> </strong>to read about what sets us apart, or<a href="https://www.citruslabs.com/post/hear-from-our-patients-how-citruslabs-modernizes-clinical-trials"><strong> here</strong></a><strong> </strong>to read what our patients have to say about us.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=df89ec1e9eed" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[4 aims for heart health clinical trials in 2020]]></title>
            <link>https://medium.com/@citruslabs/4-aims-for-heart-health-clinical-trials-in-2020-d091a13e9e79?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/d091a13e9e79</guid>
            <category><![CDATA[medical-research]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[heart-disease]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Fri, 31 Jul 2020 14:12:52 GMT</pubDate>
            <atom:updated>2020-07-31T14:12:52.404Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*rp5DraR87eGEok5RNryt-A.jpeg" /></figure><p>It’s been a tough year for all clinical research — particularly that of heart health. With over 440 clinical trials suspended since March 1st, many of which directly relate to heart research, some of the world’s deadliest diseases are no closer to being cured. The current issue, beyond this major health crisis, concerns itself with patient confidence and patient recruitment statistics today. With 15–20% of research sites failing to recruit a single patient for their clinical studies, it’s unlikely that finding cures for heart disease or stroke is going to be possible when trial recruitment is already improbable.</p><p>Stroke has been one of the world’s most prominent killers for decades now and, with COVID-19 being directly linked to cardiovascular disease and lung failure, there is — now more than ever — a mandate to change this normality. Today, we lay out <strong>4 aims for heart health clinical trials this year</strong>; and consider what research sites and clinical trial sponsors alike can do to tackle the growing heart health crisis.</p><h3>Eliminate gender bias</h3><p>Each year, heart disease claims the lives of 1 in 3 women; and to make matters worse, 80% of these deaths could have been/can be prevented. While several studies promote the implementation of a healthy, balanced diet for decreasing the present risk, there is a large hole in heart disease research that puts women at a clear disadvantage to their male counterparts. ‘Research Goes Red’, an initiative by the American Heart Association and Verily’s Project</p><p>Baseline, looks to empower women to contribute to clinical studies and is only one of a few projects worldwide looking to eliminate gender bias in clinical research.</p><p>The fact is that, in 2014, a <a href="https://www.theguardian.com/lifeandstyle/2015/apr/30/fda-clinical-trials-gender-gap-epa-nih-institute-of-medicine-cardiovascular-disease">report</a> by the Brigham and Women’s Hospital in Boston concluded that the science that informs medicine — including the prevention, diagnosis, and treatment of disease — routinely fails to consider the crucial impact of sex and gender. This, the report finds, “hampers our ability to identify important differences that could benefit the health of all”. Not only this, but it was also found that 8 over-the-counter medications were withdrawn by the US Food and Drug Association (FDA) between 1997 and 2001 due to ‘unacceptable risks to women’s health’.</p><p>The result of excluding women means more than just restrictions on profit margins or making an “unremarkable” contribution to science. As the owners of those 8 drugs found out, inherent gender bias in clinical trials can be fatal. The clinical research industry holds women’s lives in the palm of their hands; so, saving your research’s validity also means saving lives.</p><h3>Fight racial prejudice</h3><p>Right now, BAME individuals are at a higher risk of dying from COVID-19 than their white counterparts. By the end of May, the COVID-19 mortality rate for black Americans (1 in 1,850) was 2.4 times as high as the rate for white Americans (1 in 4,400). This same<a href="https://www.apmresearchlab.org/covid/deaths-by-race"> report</a> estimates that, if they had died of COVID-19 at the rate of white Americans, around 13,000 black Americans, 1,300 Latino Americans and 300 Asian Americans would still be alive today.</p><p>So, what exactly does all this mean for heart health research? In the past, it’s been so easy for us to look the other way and label it “a political issue”, “not our responsibility” or “beyond our control”. Now, however, the situation has changed. New evidence suggests that there is a strong correlation between representation in clinical trials and the health of minority groups.</p><p>According to a recent report by the FDA, only 4% of cancer clinical trial participants are black, 4% are Hispanic, and 15% are Asian. Yet, last year, the American Cancer Society reported a near-equal rate of incidence in both white and black patients. This ultimately means that the black population is severely under-represented in trials to cure an illness that affects them just as much as white Americans. With<a href="http://www.pharmatimes.com/web_exclusives/addressing_the_diversity_challenge_in_clinical_trials_1285691"> studies</a> showing that certain peoples can respond to the same medical therapy very differently, a lack of diversity is not only damaging from a moral perspective, but it may also have potentially dangerous, undocumented results on part of the population.</p><p>Much like what is happening on social media with black awareness at the moment, heart health clinical research must act as thought-leaders in clinical trial education. It’s documented by the FDA in<a href="https://www.fda.gov/news-events/fda-voices/fda-addresses-health-disparities-through-communication-research-and-collaboration"> a recent post</a> that minority populations may lack the core knowledge about clinical research opportunities, which, in turn, contributes to lower rates of representation in clinical trials. Yet, education on clinical studies should not just be for certain groups — it must be for all. In fact, a recent survey by Clinical Leader found that<a href="https://www.clinicalleader.com/doc/survey-of-americans-not-aware-of-clinical-trials-0001"> two-thirds of all respondents</a> didn’t know whom clinical trials are targeted at, with high levels of stigma surrounding the topic of clinical research overall.</p><h3>Continue to educate</h3><p>The answer to the first two problems, as I have already alluded to, lies in education. Beginning in schools and ending in older years’ health courses, the importance of healthy dieting and lifestyle choices must be fundamental to everyday life. That fact is that around half of all Americans are not aware that clinical trials even exist.; and if we can take anything for this, it is that a lack of familiarity equals a lack of confidence.</p><p>In today’s society, there is a nationwide “not for me” attitude that can be easily countered by education. Success here comes down to research sites building a strong feasibility analysis (check out our top tip for managing your feasibilities<a href="http://www.citruslabs.com/single-post/2020/01/10/3-clinical-research-mistakes-to-avoid-A-Biogen-breakdown"> here</a>.) A plan that targets a specific demographic with the right, relatable sound bites is sure to counteract any concern. Use the data gathered from your initial research to outline your ideal candidate and relinquish any misconceptions. Share, retweet or regram to let people know if they can get involved. In short, focus your early efforts on spreading awareness. At the end of the day, the goal of research sites everywhere should be to make participation in clinical studies the accepted, the norm and the “for me”.</p><h3>Consider virtual trials</h3><p>Last month, a survey by digital analytics firm, McKinsey &amp; Company, found that more than 75% of consumers asked have experimented with alternative methods of shopping, such as the use of online shopping and delivery services. When we compare this with the fact that 4.57 billion people are online today, it’s clear that the developed world has now developed technology into their everyday routines. So, how do heart health clinical studies benefit from this?</p><p>Round-the-clock monitoring of a patient’s lifestyle choices is now a reality with the development of wearable tech. Today, clinical research shouldn’t have to rely as heavily on probability when it comes to determining the best course of action for treatment. Practitioners can now closely observe the patterns of their patients and intervene quickly if any unexpected incidents arise.</p><p>Recent developments from companies like Pfizer, Science 37 and Aicure also prove that clinical research can reap a wealth of benefits from virtualization (check out our breakdown of these developments<a href="https://www.citruslabs.com/post/virtual-clinical-trials-why-the-future-starts-now"> here</a>). Clinical trials are often delayed or fail due to difficulty recruiting research participants, and it is evident that virtual trials — especially in recent years — outshine their traditional counterparts in terms of recruiting successfully.</p><p>Virtual trial recruitment notes that distance, disability, and the need for frequent in-person visits are major barriers to participation in trials with standard clinical protocol; with a<a href="https://n.neurology.org/content/71/23/1883.short"> study</a> in Alzheimer’s disease finding that home visits were the factor most likely to enable greater participation. The fact is that virtual research visits could reduce the time and travel burden of participating in research.</p><p>Carrying out clinical trials from the comfort of the participant’s home is the invaluable and entirely unique benefit of virtual trials. As public opinion sways towards safety and security above all else, when it comes to going digital, we recommend the sooner, the better.</p><p>Here, we’ve created the ideal<a href="https://www.citruslabs.com/for-sites"> patient recruitment dashboard</a> to help researchers improve their current metrics. With <strong>over 3 million patients on record</strong>, we ensure research sites are connected to a thoroughly educated and engaged pool of participants; so, it is no wonder why we have such high patient confidence! Now, we would say that other models are available — but this would be a lie. In fact, unlike that offered by other patient recruitment companies, our easy-to-use dashboard is <strong>the first-of-its-kind for the market</strong>; giving researchers a unique insight into their patients’ wants and needs via industry-leading technology. The future of clinical recruitment starts<a href="http://citruslabs.com/"> here</a>.</p><ul><li><strong>Interested in finding out more? Get in touch with us</strong><a href="https://www.citruslabs.com/contact"> <strong>here</strong></a><strong>, and check out our</strong><a href="https://www.citruslabs.com/blog"><strong> archives</strong></a><strong> for all our top tips and tricks on running successful clinical trials in today’s constantly changing industry.</strong></li></ul><p>Still a little unsure? Check out what our customers have to say about us<a href="https://www.citruslabs.com/casestudies"> here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d091a13e9e79" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[News: Irish pharma looks to raise $300 million for phase 1 clinical trials]]></title>
            <link>https://medium.com/@citruslabs/news-irish-pharma-looks-to-raise-300-million-for-phase-1-clinical-trials-46529b068ce0?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/46529b068ce0</guid>
            <category><![CDATA[pharma]]></category>
            <category><![CDATA[medical-research]]></category>
            <category><![CDATA[patient-management-system]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Fri, 31 Jul 2020 14:08:45 GMT</pubDate>
            <atom:updated>2020-07-31T14:09:10.492Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*go9OhutYcmSkjeMBsKCFTw.jpeg" /></figure><p>Yesterday, it was reported that Atxa Therapeutics, an Irish pharma tackling a form of cardiovascular disease, is on a mission to raise funds to support phase 1 clinical trials of their NTP42 drug. With investors and clinical trial sponsors already vocalizing their interest, the project appears to be off to a promising start. Founder and chief executive of the company, Prof Therese Kinsella, told <em>The Irish Times</em> that the funding was essential to clinical trials thought to start in the first quarter of 2021, with the remainder of the funds being used to secure marketing authorization for the drug once tested.</p><p>Axta Therapeutics’ compound looks to not only stop the progression of a cardiovascular condition called ‘pulmonary arterial hypertension’ (or PAH for short), but in fact reverse the overall effects of the disease. Affecting as many as 500,000 people worldwide, PAH is a</p><p>progressive disorder that weakens the inner muscle of our lung arteries and forces the heart to work harder to pump blood through the lungs. What happens if the condition is left untreated can be devastating. Often, patients are left with breathing difficulties and heart failure; with most people surviving no more than three years living with the condition.</p><p>There are a few treatment methods that can, thankfully, allow patients to extend their life expectancy significantly. Medications to prevent blood clots, diuretics to remove excess fluid in the body, and digoxin to slow down the heart rate and strengthen the heart muscle, are all available to those diagnosed. The main issue for research sites today not only lies in finding a cure, but in the cost of current medications. It’s estimated that PAH costs $6 billion every year to treat; and it might be that Atxa Therapeutics could help reduce these costs.</p><h3>Obstacles in the way</h3><p>It’s well known that trial recruitment is a daunting and stressful affair regardless of the therapeutic area you specialize in. This is why, on average, 86% of clinical trials fail to meet their patient recruitment targets. When it comes to heart health clinical research, an <a href="https://www.ncbi.nlm.nih.gov/books/NBK92105/">article</a> published by the <strong>US Institute of Medicine</strong> (USIM) finds issues with recruitment and patient engagement begin with research sites. The report cites a lack of ‘clinical trial culture’, open communication, and patient trust in the medical community as only a select few of the patient recruitment challenges facing cardiovascular research today.</p><p>With an ongoing <a href="https://continuumclinical.com/blog/covid-19-live-updates">survey</a> by Continuum Clinical finding, back in March, that <strong>81% of research sites reported high levels of unwillingness by patients to continue with participation</strong>, it’s clear that a clinical trial recruitment crisis was sparked over the lockdown period. What this means is that the situation may be far worse than expected. These preexisting issues outlined by the USIM article must now be considered to have a far more severe impact on the clinical research industry than initially thought. As Swiss biopharma and industry giant, <strong>Novartis</strong>, was only a few weeks ago forced to halt their phase 1 clinical trials due to patient recruitment issues, clinical recruitment today is a minefield of error — even for the industry leaders!</p><p>While Atxa Therapeutics still has a grilling funding process ahead of them before any clinical research can get underway, the future looks bright for the ‘UCD Spinout’ company and for patients of the complicated disease. With the right funding by clinical trial sponsors, Atxa may be able to unlock the secret to reversing the life-threatening condition. To ensure that the trial recruitment process runs smoothly, however, the firm may choose to turn to patient recruitment companies for added security. As patient confidence reaches a record low, we can only wait and see how the pharma approaches this mountainous challenge; and how they overcome this may be the difference between a treatment and a cure for PAH.</p><p>Here at Citruslabs, we’ve created the ideal<a href="https://www.citruslabs.com/for-sites"> patient recruitment dashboard</a> to help any researcher improve their current metrics. With <strong>over 3 million patients on record</strong>, we ensure research sites are connected to a thoroughly educated and engaged pool of participants; so, it is no wonder why we have such high patient confidence! Now, we would say that other models are available — but this would be a lie. In fact, unlike that offered by other patient recruitment companies, our easy-to-use dashboard is <strong>the first-of-its-kind for the market</strong>; giving researchers a unique insight into their patients’ wants and needs via industry-leading technology. The future of clinical recruitment starts<a href="http://citruslabs.com/"> here</a>.</p><ul><li><strong>Interested in finding out more? Get in touch with us</strong><a href="https://www.citruslabs.com/contact"><strong> here</strong></a><strong>, and check out our</strong><a href="https://www.citruslabs.com/blog"><strong> archives</strong></a><strong> for all our top tips and tricks on running successful clinical trials in today’s constantly changing industry.</strong></li></ul><p>Still a little unsure? Check out what our customers have to say about us<a href="https://www.citruslabs.com/casestudies"> here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=46529b068ce0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How diabetes clinical trials work]]></title>
            <link>https://medium.com/@citruslabs/how-diabetes-clinical-trials-work-67c5703c339b?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/67c5703c339b</guid>
            <category><![CDATA[diabetes-treatment]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[medical-research]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Fri, 31 Jul 2020 14:02:11 GMT</pubDate>
            <atom:updated>2020-07-31T14:02:11.773Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XO919YVgQ2UmquivvgCpjA.jpeg" /></figure><p>It’s surprising how hard it is to remember life before coronavirus — and when we stop to do so, the last thing we want to think about is yet another health crisis, but here we are. Before the pandemic sent everyone into lockdown, the Western world was already battling what health experts then claimed to be “the greatest health crisis” facing society today. The silent pandemic, diabetes, claims the lives of more than 500 people in the UK every week. With Type 2 patients <strong>2.5 x more likely to experience heart failure</strong> and nearly 2.5 x more likely to have a heart attack and/or stroke than your average Joe, it’s clear that more needs to be done to spread awareness and increase prevention.</p><p>Today, we shine a light on the latest diabetes clinical trials and let you know how you can get involved from the comfort of your own home. Check out our breakdown below.</p><h3>What’s the buzz?</h3><p>According to the American Diabetes Association, there are 5 key areas of diabetes research funded by the organisation today; all with their own unique clinical protocol and approaches. Much has changed from the early studies of the pancreas over 100 years ago, with research sites now focusing their clinical research in a range of areas such as proteins, genetics, and cell mutation. Here’s a brief overview of the latest clinical studies in each of the 5 areas.</p><p><strong>Type 1</strong></p><p>Right now, doctors can accurately predict a high risk of type 1 diabetes (T1D) by the means of a few short genetics and blood tests; what is not available yet is a method of prevention. Kenneth Brayman, MD, PhD, of the University of Virginia is currently studying a factor he identifies as IgM that’s been shown to cause immune cell dysfunction in people with T1D. What appears to happen next is that this triggers a defense mechanism in the body in which it counter-productively attacks its insulin-producing cells.</p><p>Dr Brayman’s clinical research is looking to start phase 1 clinical trials asap, with initial research finding that IgM transplants from healthy human donors prevented T1D progression in mice. If successful, Brayman’s factor could offer people at high risk a direct method of avoiding a potentially life-long and life-threatening condition.</p><p>Over at the University of California, Qizhi Tang, PHD, has recently published the findings of her study into the transplantation of insulin-producing cells. The clinical research looks to spare T1D patients from daily finger-pricks and insulin injections that have become part of everyday life for those with the condition. Much like Dr Brayman’s work, Dr Tang is currently experimenting with the possibility of a surgical procedure that would give patients independence from their condition.</p><p>Overall, successfully converting stem cells into insulin-producing cells could give researchers the possibility of a limitless supply of cells to transplant. With this approach, it may become possible for all people with T1D to eliminate the need to administer insulin.</p><p><strong>Type 2</strong></p><p>While there is still no known cure, many studies into type 2 diabetes (T2D) prove that it can be reversed through dietary and lifestyle changes. This is because, in most cases, T2D is developed by people due to various environmental and socioeconomic factors. In 2018, Cholsoon Jang, PhD, of Princeton University explored the link between soda and the disease; finding that fructose, a key element of the drink, when consumed in high dosages overwhelms the normal intestinal disposal route and enters the bloodstream, ultimately causing toxicity in the liver and increasing risk for T2D. The study ultimately highlights the core link between excess in diet and the disease.</p><p><strong>Insulin Resistance</strong></p><p>The condition that precedes type 2 and affects as many as 1 in 3 Americans is seeing producing promising findings in gene and hormone research. At the University of Utah, researchers have identified humans with genetic variants which leave them susceptible to insulin resistance. Insulin resistance prevents insulin from promoting glucose uptake into cells. Today, Dr. Scott Summers and his team are working to determine how changes in diet prevent or exacerbate development of insulin resistance.</p><p><strong>Obesity</strong></p><p>Over the last few decades, obesity rates in the West have continued to rise; with the risk of type 1 and type 2 diabetes rising with it. To reduce the burden of diabetes, research efforts focused on the biology of weight regulation and new approaches to support people losing weight and sustain weight-loss are vital. Juli Bai, PhD, at the University of Texas has identified a gene which influences the amount of energy that is expended by the body, which may be the key to lowering the risk of obesity and diabetes in patients. In this project, Dr. Bai is working to further investigate this gene and to determine if it might be a therapeutic target to help people lose weight.</p><p><strong>Gestational Diabetes</strong></p><p>Occuring during pregnancy and typically resolved after the baby’s birth, gestational diabetes affects as many as 1 in 10 pregnant women and increases the risk of development of type 2 in both the mother and the child. Dr Erika F.Werner’s project at the Women and Infants Hospital of Rhode Island will determine how we can change postpartum care to better identify women with prediabetes and then intervene to reduce their diabetes risk. Three hundred women with GD will receive routine care to compare the women who return for postpartum glucose testing to those who do not return. Dr. Werner will also compare individual characteristics, barriers to care and attitudes toward healthcare among the two groups.</p><h3>Get involved</h3><p>Interested in getting involved in diabetes clinical trials? Take a look at the options below for a few ideas on how you can make a difference to this area of clinical research.</p><p>For patients:</p><p>Mindmate,<strong> the #1 health app</strong>, is the perfect everyday solution for monitoring your health and keeping up-to-date on the latest clinical studies in your local area. With free access to a wealth of brain-training games, easy-to-make recipes and step-by-step workout regimes, <a href="http://mindmate-app.com/">Mindmate</a> is your new digital health diary and planner. Not only this, the app gives you access to virtual clinical trials and online questionnaires in one tap; allowing you to play your part in the crucial clinical research happening across the globe from the comfort of your own home.</p><p>For research sites / CROs / independent researchers:</p><p>Here, we’ve created the ideal<a href="https://www.citruslabs.com/for-sites"> patient recruitment dashboard</a> to help researchers improve their current metrics. With <strong>over 3 million patients on record</strong>, we ensure research sites are connected to a thoroughly educated and engaged pool of participants; so, it is no wonder why we have such high patient confidence! Now, we would say that other models are available — but this would be a lie. In fact, unlike that offered by other patient recruitment companies, our easy-to-use dashboard is <strong>the first-of-its-kind for the market</strong>; giving researchers a unique insight into their patients’ wants and needs via industry-leading technology. The future of clinical recruitment starts<a href="http://citruslabs.com/"> here</a>.</p><ul><li><strong>Interested in finding out more? Get in touch with us</strong><a href="https://www.citruslabs.com/contact"><strong> here</strong></a><strong>, and check out our</strong><a href="https://www.citruslabs.com/blog"><strong> archives</strong></a><strong> for all our top tips and tricks on running successful clinical trials in today’s constantly changing industry.</strong></li></ul><p>Still a little unsure? Check out what our customers have to say about us<a href="https://www.citruslabs.com/casestudies"> here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=67c5703c339b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The 4 pillars of ethical trial practice]]></title>
            <link>https://medium.com/@citruslabs/the-4-pillars-of-ethical-trial-practice-5af5053c6dd0?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/5af5053c6dd0</guid>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[ethics]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Wed, 08 Jul 2020 16:08:10 GMT</pubDate>
            <atom:updated>2020-07-08T16:08:10.068Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*o9i3grDDaTWxFBZ_XaF0Gg.jpeg" /></figure><p>In recent times, the efficacy of specific COVID cure candidates, such as hydroxychloroquine, has amassed much speculation; with the FDA, late last month, officially revoking the named substance for emergency use due to its potentially dangerous side-effects. While progress continues to be made in this area, a similar spotlight must be put on the ethics of these trials. As a <a href="https://www.bma.org.uk/media/2360/bma-covid-19-ethics-guidance-april-2020.pdf">report</a> by the <strong>British Medical Association </strong>details, a list of criteria has been introduced to reassure doctors of their actions during these uncertain times; underlining the importance of ethical conduct today.</p><p>While the Good Clinical Practice (GCP) guidelines are now mandatory for most operating clinical trials, it is nevertheless important that research sites brush up on their knowledge of ethical practice from time to time. Even the smallest neglect of clinical protocol can endanger not only the trust of your participants but the credibility of your entire project! Today, we take a look at <strong>the 4 key principles of successful ethical practice</strong> and consider their impact on the research production line.</p><h3>Confidentiality</h3><p><em>Consider the privacy of those involved and the potential bias that could result if discretion is not maintained.</em></p><p>Confidentiality doesn’t begin and end with data protection and patient discretion; in fact, it encompasses a far wider range of issues. One of these concerns itself with the anonymity of patients during the trial itself — and <strong>it could mean the difference between a trial starting as double-blinded and ending as unblinded</strong>. The monitoring of side-effects and regulation of information pertaining to the effects of treatments must be carefully managed by the use of an effective risk-management strategy. If, for instance, a number of treatment group patients begin to develop significant side effects, clinical investigators should be equipped with patient management skills in order to keep treatment and placebo groups from identifying their category. This, in addition to randomization in the early stages of planning, should ensure that any bias is contained.</p><h3>Responsible publication</h3><p><em>Consider the legal implications of what you state publicly and beware the potential legalities involved (e.g. copyright laws).</em></p><p>To earn that FDA stamp of approval — and avoid potential legal action — CROs must look to create their own system of checks and balances. In the drafting of the <strong>feasibility analysis</strong> (see <a href="https://www.citruslabs.com/post/2020/01/10/3-clinical-research-mistakes-to-avoid-a-biogen-breakdow">here</a> for more information), the researcher should redirect some of the workload to a specialized sub-group handling any publications made by the company, both commercial and legal. Clinical trial agreements (CTAs), the contract signed by a researcher and their sponsor, differ from trial to trial; and so, no one-size-fits-all template can be produced. When it comes to liabilities and intellectual property rights, these contracts seem to produce a stark contrast from one another. So, it is safe to say that having a legal expert take the lead here is a strong managerial move in the long-term.</p><h3>Objectivity</h3><p><em>Consider your interests (financial or personal gain) in the study and remove them from the equation. Focus on the patient.</em></p><p>Not only is it important for the researcher to maintain scientific objectivity, but it is also crucial that their study is patient-centric. Literally meaning ‘patient at the centre’, patient centricity has become a bit of a buzzword among research institutions over the last couple of years. The term is thought to have originated from the UK NHS’ ‘no decision about me, without me’ initiative, and fundamentally promotes the role of the patient in the clinical trial process; ultimately keeping the study as objective as possible.</p><p>The key to patient-centricity is knowing how much work you can take on at one time, while not hindering your patient-care protocol. As we’ve previously stated in our checklist for starting a trial (check it out<a href="https://www.citruslabs.com/post/planning-a-clinical-trial-our-checklist-for-getting-started"> here</a>), it’s totally natural for researchers to feel like they want to do all the work themselves. While this is a fantastic idea, this is a highly impractical plan. It’s absolutely essential that researchers form connections with like-minded individuals in order to break down the work and lighten the burden of their workload. This is why patient recruitment companies are an essential. PRCs allow researchers<strong> access to databases full of loyal candidates, </strong>saving them the essential time to focus on further patient-care. Most PRCs will also run other services targeted at potential patients, and by doing so they will have built up years worth of respect within their customer community — resulting in a big win for objective research.</p><h3>Social responsibility</h3><p><em>Consider what your research will improve in the world and strive to make a positive change.</em></p><p>To the benefit of clinical research, the world is currently redefining what ‘social responsibility’ means; in the 12 hour shifts of front-line workers and in the persistent passion of the Black Lives Matter movement. The latter of the two provides a particularly clear basis for research going forward as the inherent racial prejudice brought to light over the last few months is something that can be dismantled from inside the industry.</p><p>The fact is that BAME individuals are, right now, <strong>at a higher risk of dying from COVID-19 than their white counterparts</strong>. By the end of May, the COVID-19 mortality rate for Black Americans (1 in 1,850) was <strong>2.4 times as high </strong>as the rate for white Americans (1 in 4,400). This same<a href="https://www.apmresearchlab.org/covid/deaths-by-race"> report</a> estimates that, if they had died of COVID-19 at the rate of white Americans, around 13,000 black Americans, 1,300 Latino Americans and 300 Asian Americans would still be alive today.</p><p>In the UK, the situation is not any better — in fact, in many areas, it is far worse. The first statistics concerning the spread of the virus, released back in April, reported that around<strong> 33% of patients in intensive care were BAME</strong>; and these numbers are strikingly disproportionate when we consider that <strong>the groups make up only around 14% of the population</strong>. Not only this, according to<a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19roundup/2020-03-26"> the Office for National Statistics</a>, black men in the UK are 4.2 times more likely to die from the coronavirus than their white counterparts.</p><p>It’s up to researchers to bear the weight of these statistics and let the wider community know they understand the human cost behind the numbers. Social responsibility isn’t just a soundbite or a marketing device, <strong>it is an obligation held by CROs to society</strong>; and, most importantly, it is the foundation on which successful research is built.</p><p>Here at Citruslabs, we’ve created the ideal <a href="https://www.citruslabs.com/for-sites">patient recruitment dashboard</a> to help any researcher improve their current metrics. Linked to<strong> our #1 health app in 17 countries</strong>, Mindmate, our patient recruitment dashboard directly connects researchers to <strong>over 3 million registered patients</strong>. Now, we would say that other models are available — but this would be a lie. In fact, our easy-to-use dashboard is <strong>the first-of-its-kind for the market</strong>; offering researchers a unique insight into patients’ wants and needs via industry-leading technology. The future of clinical recruitment starts <a href="http://citruslabs.com/">here</a>.</p><p>Still a little unsure? Check out what our customers have to say about us <a href="https://www.citruslabs.com/casestudies">here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5af5053c6dd0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Post-covid: ethical practice for clinical trials]]></title>
            <link>https://medium.com/@citruslabs/post-covid-ethical-practice-for-clinical-trials-8b9804e40775?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/8b9804e40775</guid>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <category><![CDATA[ethical-research]]></category>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[patient-engagement]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Wed, 08 Jul 2020 16:03:44 GMT</pubDate>
            <atom:updated>2020-07-08T16:04:02.007Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7VnK8W55JEIZZKBnCROCyg.jpeg" /></figure><p>Late last month, a coronavirus vaccine developed by <strong>Bharat Biotech</strong> became the first of its kind to be approved for human trials in India. Though, in recent days, the Indian Council of Medical Research has established its want to launch this same vaccine for public health use by August 15th 2020. This announcement, understandably, has been questioned by independent experts due to the short time-scale set by the council. Among this criticism, the editor of the <em>Indian Journal of Medical Ethics</em> has publicly stated their disapproval.</p><blockquote><em>“I don’t think anywhere in the world has anyone ever given a date in advance for the release of a new vaccine before a clinical trial has even begun… that is not how science works.”</em></blockquote><p>- Amar Jesani, editor of the<em> Indian Journal of Medical Ethics</em></p><p>What research sites can take away from this is a prevalent need for transparent, ethical practice despite the confusion of the pandemic. Today, we take a look at some of <strong>the most notable developments in clinical research</strong> and consider the ethical issues that may arise in our fast-changing industry. Check out our breakdown below.</p><h3>Cancer research</h3><p>Yesterday (7th July 2020), leading biotech, <strong>Hubei Soundny</strong>, released their findings on the company’s latest project. Concerned with a treatment for cholangiocarcinoma, a form of bile duct cancer, their drug-loaded tumor therapy has been approved for clinical use due to its efficacy in its phase 1 clinical trial. Director at Nankai Hospital and co-author of the report, Zhang Hui, stated that since surgery is almost always preferred as the mode of clinical protocol, treatment is only really available in the later stages of the disease. Hubei Soundny’s drug, he claims, should offer a solution to the majority of patients not eligible for radical surgery.</p><p>While the results were positive, with <strong>30% of the patients tested entering a partial remission</strong>, it is also important to remember that this data was collected from only 20 enrolled candidates, all in their final stages of the disease with low time-frames of survival. Yes, this is not atypical of early phase trials; however, the restrictions these conditions impose on the trial’s overall success must be noted. According to an<a href="https://www.microbiologyresearch.org/docserver/fulltext/jmm/61/7/889_jmm039180.pdf?expires=1586615211&amp;id=id&amp;accname=guest&amp;checksum=ECA30BCB8C28556CAC7F7DF1882FF872"> article</a> from the <em>Journal of Microbiology</em>, too many trials today are failing to collect adequate preclinical data that, in some cases, is leading to a lack of detailed information on protective correlates of immunity. In short, studies are failing to fully detail signs of immunity in healthy patients that, in turn, contribute to product failure in clinical trials and an easing of ethical conduct.</p><h3>Alzheimer’s studies</h3><p>Axsome Therapeutics has been given the all-clear by the FDA for further investigation of their novel, oral treatment, AXS-05. The compound looks <strong>to tackle the psychological agitation connected to Alzheimer’s disease</strong> — and, with no other treatment currently available, Axsome’s chances of bringing this to market look promising. As part of their phase 2 clinical trial, ADVANCE-1, 336 patients were treated under double-blinded, randomised conditions.The result: the study successfully showed treatment with AXS-05 resulted in a rapid, substantial, and statistically significant improvement in agitation when compared to a placebo.</p><p>Again, though this news is definitely optimistic, we must also remind ourselves of the industry-wide issues facing this sort of clinical research. Findings published on the UK government website reports a staggering <a href="https://www.scientificamerican.com/article/why-alzheimer-s-drugs-keep-failing/">99.6% chance of failure</a> for Alzheimer’s drug treatments in the development stages. As no real solutions have, as a result, been brought to market successfully, therein lies an abundance of ethical concerns. Finding drugs to treat the condition is particularly difficult as the brain is relatively inaccessible and harder to test and deliver compounds to, explains <a href="http://www.psych.ox.ac.uk/team/PIs/simon-lovestone">Simon Lovestone</a>, a professor of translational neuroscience at the University of Oxford, UK. Thus, it is not merely a question of resolving ethical issues in this area — but of establishing workable, clinical protocol as we continue to learn more about the disease and the brain.</p><p>Here at Citruslabs, we’ve created the ideal<a href="https://www.citruslabs.com/for-sites"> patient recruitment dashboard</a> to help research sites improve their current metrics. Linked to <strong>our #1 health app in 17 countries</strong>, Mindmate, our patient recruitment dashboard directly connects researchers to <strong>over 3 million registered patients</strong>. Now, we would say that other models are available — but this would be a lie. In fact, unlike that offered by other patient recruitment companies, our easy-to-use dashboard is <strong>the first-of-its-kind for the market</strong>; giving researchers a unique insight into their patients’ wants and needs via industry-leading technology. The future of clinical recruitment starts<a href="http://citruslabs.com/"> here</a>.</p><p>Still a little unsure? Check out what our customers have to say about us<a href="https://www.citruslabs.com/casestudies"> here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8b9804e40775" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The best marketing methods for clinical trial awareness]]></title>
            <link>https://medium.com/@citruslabs/the-best-marketing-methods-for-clinical-trial-awareness-425c9ee05f77?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/425c9ee05f77</guid>
            <category><![CDATA[marketing-methods]]></category>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Fri, 03 Jul 2020 16:18:08 GMT</pubDate>
            <atom:updated>2020-07-03T16:18:08.441Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bRK1n5RGAf29eEyEJrfQMA.jpeg" /></figure><p>As we said in a previous article on patient-centricity (check it out <a href="https://www.citruslabs.com/post/the-latest-stats-on-patient-centricity-and-what-they-mean-for-your-research">here</a>), survey-experts<strong> IPSOS MORI</strong> revealed in a recent report that the industry today is now facing worryingly-low levels of patient confidence. Overconfidence on the part of CROs and research operators, says the study, is a resounding factor. In fact, <strong>only three in ten respondents (30%) ranked their confidence in biopharmas implementing patient-focused missions as 8/10 or more</strong>; whereas half of the biopharma associates ranked their confidence to the same degree. With Forrester Consulting’s 2019 Survey finding a <strong>35% difference in confidence</strong> between marketeers and second-party data, it’s clear that overconfidence isn’t just a research issue — but, looking at patient confidence and consumer confidence side-by-side, it may be more detrimental to the former.</p><p>Whether the root problem lies in a miscalculated feasibility or ill study planning, it’s clear that the research-patient communication involved has broken down. Today, we take a look at <strong>the best marketing strategies for research in 2020</strong> and consider how their impact could shape clinical trial awareness for the better. Check out our breakdown below.</p><h3>Traditional methodologies</h3><p>While postal questionnaires certainly are a thing of the past, some traditional methodologies are still relevant to trial marketing today. The issues arise when these particular strategies aren’t contextualized and updated to suit the needs of current candidates. The pamphlet at the doctors’ surgery is still effective — as long as it is relevant.</p><p>A simple rule of thumb for updating the old is this: <strong>make sure it’s clear</strong>. Be pragmatic and say it how it is. Research by Pixus shows that<a href="https://www.pixus.uk/blog/the-importance-of-tone-of-voice-and-why-you-should-get-it-right/"> people tend to be put off by convolution</a>. Lengthy sentence structures and flowery vocabulary are seen as elitist and not relatable to the ordinary individual. So, when it comes to the ‘how’ of communication, be concise.</p><p>Equally, the ‘what’ is just as simple. Regardless of medium, make sure people are informed about all details of the study — or at least as much as they can know. Be sure to include the duration, location, time, etc. to ensure patients are confident with the study’s purpose. For legal reasons, all risks must be put to the candidate upfront; but, remember that it doesn’t have to be all doom and gloom.<strong> A successful risk-communication strategy isn’t about bluntness — it’s about being knowledgeable, and being able to simplify the knowledge in a way that is understandable</strong>. Again, be pragmatic and think sensibly. Don’t make potential candidates worry for their health but don’t straight up lie either. Clarity is a tough skill to gain, but it’s one that any researcher should master in order to obtain and maintain high patient engagement.</p><p>Let potential candidates and current patients know that you are open to <strong>telephone interviews</strong> and <strong>email correspondence</strong>. For those in the UK, applications such as <strong>MyGP</strong> are now available to eliminate the backlog of appointment requests and provide a less daunting method for patients to disclose their concerns. More options for communication means more time for researchers to form considered and helpful responses to patients’ issues. Ultimately, widening accessibility works towards eliminating the stigma surrounding the researcher-patient consultation.</p><h3>Digital methodologies</h3><p>With around <strong>4.57 billion people now online</strong> (as of April 2020), technology, as we now know it, is no longer a toy-thing for the younger generations. Coronavirus-induced isolation has seen <strong>an increase in social media usage across a variety of age groups</strong>, with more people now using a smartphone or smart-device than previously recorded. Technology truly has saved us from boredom and connected us with our loved ones when we physically can’t; and, for the benefit of clinical research everywhere, this dependency on tech will continue long after the elimination of the virus.</p><p>Patient recruitment, when making full use of technology, has the potential to completely revamp the outcomes of clinical research. On average, <strong>86% of clinical trials do not meet patient recruitment targets</strong>, with this kind of worrying statistic long accepted as a commonplace occurrence in the industry. So, if the world is now pretty tech-savvy and our past methods of patient-recruitment appear to be failing us, it’s only common sense that the patient-recruitment crisis must have a technologically-inspired solution.</p><p>Digital marketing and automated recruitment dashboards are now the necessities of any clinical researcher. As we now have a high population of ideal candidates using technological applications, the modern researcher must make use of technology that can directly target patients and can efficiently process data from these interactions. The establishment of a social media presence and the use of a patient recruitment dashboard is bound to take the stress out of a traditionally low-success procedure.</p><p>For a fuller guide to clinical trial marketing, check out Citruslabs’ own <a href="https://www.citruslabs.com/post/the-4-e-s-of-patient-engagement">4 ‘E’s of patient engagement</a>. A quick but comprehensive manual, our 4 ‘E’s provide the ideal checklist for researchers of all expertise and monetary situations.</p><p>Here at Citruslabs, we’ve created the ideal <a href="https://www.citruslabs.com/for-sites">patient recruitment dashboard</a> to help any researcher improve their current metrics. With<strong> over 3 million patients on record</strong>, we ensure researchers are connected to a thoroughly educated and engaged pool of participants; so, it is no wonder why we have such high patient confidence! Linked directly with <strong>our #1 health app in 17 countries</strong>, <a href="https://www.mindmate-app.com/">Mindmate</a>, our <a href="https://www.citruslabs.com/for-sites">patient-recruitment dashboard</a> provides researchers access to our patient database via an easy-to-use interface that is guaranteed to streamline any clinical trial.</p><p>Interested in finding out more? Get in touch with us <a href="https://www.citruslabs.com/contact">here</a>, and check out our<a href="https://www.citruslabs.com/blog"> archives</a> for all our top tips and tricks on running a successful clinical trial in today’s constantly changing industry.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=425c9ee05f77" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[COVID-19 update: virtual trials and digital recruitment increase]]></title>
            <link>https://medium.com/@citruslabs/covid-19-update-virtual-trials-and-digital-recruitment-increase-c51f31062002?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/c51f31062002</guid>
            <category><![CDATA[technolo]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[virtual-trials]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Fri, 03 Jul 2020 16:15:41 GMT</pubDate>
            <atom:updated>2020-07-03T16:16:04.057Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1BxrL4eWwL5tmOkgI_aIYw.jpeg" /></figure><p>It is no surprise to most that lockdown and social-distancing measures would mean a temporary reinvention of the standard protocol — but what many did not realize was that the temporary would soon be the new norm. A <a href="https://virtualtrials.ert.com/?utm_source=cision&amp;utm_medium=pr&amp;utm_content=0603-prrelease-pagelaunch&amp;utm_campaign=virtual-virtualsurvey">study</a> published at the start of last month (June 2020) by clinical data specialists, ERT, reveals a <strong>33% increase in the number of research organizations now using virtual trial approaches</strong>. Interestingly, this same report notes just under 10% of those surveyed had no need to employ virtual methods in the future; establishing a want for digital trial methodologies firmly in the majority of general opinion.</p><p>This news comes only weeks after the health tech firm Tabula Rasa Healthcare (TRHC) announced their partnership with Regence that will see <strong>a series of virtual trials put into operation to test COVID-19 candidate drugs</strong>. With the help of MedWise technology, the partners will look to analyze patient data in search of a “risk score”, highlighting the impact of the tested drugs on a patient’s existing drug regime. The role of technology here will <strong>practically diminish existing risk factors</strong> in these experimental trials as researchers will be able to identify potentially hazardous coronavirus therapies without actually exposing anyone to the substances in question.</p><p>When asked about the importance of virtual trial technology to the progress of COVID-19 research, Chief Scientific Officer at TRHC, Dr Jacques Turgeon, explained to Clinical Trial Arena:</p><p>“In the current situation, the risk-benefit ratio of proposed repurposed or new therapies is difficult to determine, as there is not nearly enough evidence on the efficacy of the proposed treatments nor on their safety. Our virtual approach rapidly provides information on the safety of each therapy.”</p><h3>Why virtual trials?</h3><p>The thing is that virtual trials make a lot of sense in today’s ever-changing climate. It’s thought that <strong>the most significant factor</strong> currently contributing to a lack of patient and public involvement in research is <strong>a lack of awareness</strong>, both among the general public and the medical community; and educating the masses about clinical research is something that virtual trials have an advantage in. <a href="https://www.alzheimersresearchuk.org/about-us/our-influence/policy-work/position-statements/getting-people-involved-dementia-research/">Surveys</a> show that <strong>89% of the UK public would want to take part in clinical research</strong> if they were diagnosed with a medical condition or disease, yet more than <strong>four in five people wouldn’t know how to volunteer</strong>. Similarly, 86% of UK physicians surveyed were not aware of any research in their area of study that was recruiting patients, but <strong>93% would recommend participation to patients</strong>. It’s evident that it is a lack of information — and not a lack of want — that is the issue here.</p><p>Virtual trials accommodate this need as not only do they provide flexibility for both the researcher and the patient during the trial itself, but they also make the study far more accessible from the get-go. A successful virtual trial <strong>can connect all information pertaining to the clinical study to a range of digital platforms shared by the researcher and the wider public</strong>; everything from social media through to review and comparison sites. Trials can even be directly linked to the company website, meaning potential <strong>patients can sample the study before they buy (so to speak)</strong>. Accessibility is something that virtual clinical trials exceed and, as the world continues to demand more simplicity at greater speeds, the virtual trial could soon dominate the market.</p><h3>Why digital recruitment?</h3><p>On average, worldwide, around <strong>86% of clinical trials fail to meet recruitment targets</strong> — and this was estimated before the impact of the pandemic! To add to the injury, this particular issue is not just subject-specific — it’s actually industry-wide. It’s estimated by a <a href="https://academic.oup.com/jnci/">report</a> for the National Cancer Institute that <strong>one-fifth of all cancer clinical trials fails due to recruitment-related issues</strong>. Similar numbers were, unfortunately, found in dementia research, with Alzheimer’s Research UK finding <strong>only 5.3%</strong> of the 451, 561 people formally diagnosed with dementia in England took part in a clinical trial from 2015–16. It’s clear that current recruitment metrics just aren’t cutting it, and so it’s not hard to see why digital recruitment is a viable alternative.</p><p>The fact is that digital recruitment appeals to some of the core elements of today’s society — and not solely to research enthusiasts, as previous methods have relied on for success. According to data gathered in April 2020, there are <strong>approximately 4.57 billion people now online</strong>, with the recent rise of ‘big data’ emerging from the healthcare industry meaning that trials may need to seriously consider this growth in usership (for more information on ‘big data’, check out our guide to the topic<a href="https://www.citruslabs.com/post/big-data-solving-the-big-issues-of-clinical-research"> here</a>). Ultimately, this means that how we understand patients’ wants and needs has fundamentally changed over the course of just a few years; and so the old days of paper surveys and postal questionnaires are practically behind us.</p><p>This also means that the traditional ideas of how certain groups in society communicate have now become stereotypes. According to the latest figures produced by Facebook, <strong>62% of online seniors </strong>(that is, people 65 or older who regularly use the internet) <strong>have a registered profile on the site</strong>, indicating that the older population is now more tech-aware than ever before. Patient recruitment — especially for trials concerning this particular age group, such as Alzheimer’s and dementia research — are <strong>now strongly recommended</strong> to invest in digital technologies to appeal to potential patients.</p><p>Here at Citruslabs, we’ve developed software for this very demand. Our <a href="http://citruslabs.com/">patient-recruitment dashboard</a> gives researchers access to a database with data from<strong> over 3 million patients on record</strong>. If that isn’t enough, our patient network also draws from the leading app for baby boomers and the <strong>#1 health app across 17 countries</strong>. We make it our priority to ensure that patients are educated and interested in the trial process, and so it is not hard to see why we have a track record in producing high patient confidence!</p><p>Want to find out more? Get in touch with us<a href="https://www.citruslabs.com/contact"> here</a>, or check out our<a href="https://www.citruslabs.com/blog"> archives</a> for all our top tips and tricks on how to adapt your study for today’s ever-changing industry.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c51f31062002" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Patient recruitment: our top 4 methods for 2020]]></title>
            <link>https://medium.com/@citruslabs/patient-recruitment-our-top-4-methods-for-2020-c425a1192343?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/c425a1192343</guid>
            <category><![CDATA[patient-recruitment]]></category>
            <category><![CDATA[patient-engagement]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Mon, 29 Jun 2020 16:48:43 GMT</pubDate>
            <atom:updated>2020-06-29T16:48:43.827Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*35CiSWK-gfSS03dAkmF72Q.jpeg" /></figure><p>Right now, there is still a lot of uncertainty over the state of patient confidence in health-research. While hospitals across the US and UK are reporting an increase in patient confidence, similar can not be said for research facilities. It was only a matter of months ago that Continuum Clinical’s <a href="https://continuumclinical.com/blog/covid-19-live-updates">ongoing study</a> into <strong>COVID-19’s impact on trials</strong> showed that<strong> 81% of European sites surveyed</strong> had indicated already-enrolled patients were <strong>“much less or somewhat less likely”</strong> to continue participating in trials. It is equally important to remember that, on average, around <strong>86% of clinical trials worldwide</strong> do not meet their recruitment targets, with <strong>15–20% of sites failing to recruit a single patient</strong>. Therefore, it is now vital that the industry reevaluate current recruitment methodologies to change the norm and provide some certainty.</p><p>Starting with the most traditional approaches and ending with industry-leading methodologies, <strong>our breakdown aims to increase patient recruitment rates</strong> — and even save researchers some time and money along the way. As a side note, we also strongly recommend coordinators implement all or a combination of these methods to boost patient engagement and trial awareness to their fullest potential. Check out our breakdown below for more information.</p><h3>1. Doctors’ surgeries / clinics</h3><p>While we would recommend researchers use more advanced methods of recruitment, there still are some advantages to being a bit traditional. Over the last two years, <strong>the number of patients visiting doctors’ surgeries has risen by a third</strong>, an NHS<a href="https://digital.nhs.uk/data-and-information/publications/statistical/general-and-personal-medical-services"> report </a>reveals; meaning that clinics are now busier than ever. Though this isn’t necessarily good news for overworked doctors, it may be beneficial for researchers in need of patients. By advertising at clinics and redistributing the patient’s attention to long-term research, it is thought that clinical trials may be able to help alleviate this burden felt by the health service.</p><p>The NHS Constitution makes clear that clinical research is a core function of the NHS, meaning that clinics are obliged by their code of ethics to support local research. Get in touch with your local clinics directly and arrange a meeting with the management team. Make sure you have your <strong>research plan</strong> and <strong>feasibility analysis</strong> prepared (check out our advice on this particular topic <a href="https://www.citruslabs.com/post/2020/01/10/3-clinical-research-mistakes-to-avoid-a-biogen-breakdown">here</a>). Most practices are willing to help out if you are willing to put in the extra effort at the beginning of the process.</p><p>Our top tip:</p><p>In the UK, the <strong>National Institute for Health Research</strong> runs a scheme that looks to support research studies across the country. Interested in finding out more? Get in touch with them <a href="http://nihr.ac.uk/explore-nihr/specialties/primary-care.htm">here</a>.</p><h3>2. Patient-advocacy groups</h3><p>Most areas of research will have a patient-advocacy group (PAG), in which candidates can voice their wants and needs or any fears and concerns surrounding the industry. Supplying patients with material resources and emotional support, these groups have become almost like trade unions for your potential patients. The relationship between researchers and PAGs is, on the whole, mutually beneficial: research has a channel in which to recruit and patients have a voice and often benefit from healthcare provisions provided by the company.</p><p>PAGs provide an initial point of contact for patients to trials, making it an ideal mode of recruitment for researchers on a budget. President and CEO of <strong>VOZ Advisors</strong>, Ellen Coleman, explained in <a href="https://www.anjusoftware.com/about/all-news/insights/patient-advocacy-groups#:~:text=Patient%20advocacy%20groups%20(PAGs)%20have,looking%20to%20recruit%20for%20trials">an interview</a> with ANJU, that PAGs are also essential to early market access. Allowing patients early engagement with the product allows companies to develop a drug that is needed by the patient and is able to bring about their ideal health outcomes.</p><p>Our top tip:</p><p>Always make sure to contact PAG representatives yourself; groups want to be taken seriously and so having the recruitment operator make the first point of contact shows you mean business.</p><h3>3. Digital marketing platforms</h3><p>For most people, in our digital age, the first encounter they’ll have with your study is through the company website. And if it doesn’t impress, there’s little chance they’ll say yes to anything you have to offer. A<a href="https://www.business.com/articles/7-website-design-mistakes-that-can-hurt-conversion/"> recent survey</a> for <strong>Business.com </strong>found that a whopping<strong> 75% of people judge a company’s credibility based on their website design</strong>. Website designers are expensive and this creates a dilemma for researchers with limited capital. So, how are you supposed to create an entire, polished website with little expense and no experience?</p><p>Well, it turns out you don’t need an arts degree to be creative these days. Website builders such as <strong>Wix </strong>and <strong>Wordpress</strong> offer professional templates on an easy-to-use interface. Simply drag and drop items on the page: no need to worry about code. If that wasn’t easy enough, both companies allow access to the majority of their designs and widgets for free — with premium prices at discounted rates from time to time.</p><p>Remember the following:</p><ul><li><strong>Signpost your contact information.</strong> It’s best to have multiple methods of contact for those among your targeted audience who are cautious of technology. Be sure to list your office’s name, address, and phone number on both your homepage and an easy-to-read contact page.</li><li><strong>First come, last served.</strong> Don’t go for the first design you see — think about all the other time-stretched designers that will copy and paste the same one. Look for an alternative design that could be slightly altered to fit your image. This way you avoid cliché templates while giving the design a unique twist.</li><li><strong>Be mobile-friendly.</strong> While you might have an awesome design on your laptop screen, it’s crucial to remember that a lot of your audience will be clicking your link on a mobile — not a desktop. The formatting is almost always completely different so watch out for funny layouts that can occur.</li></ul><p>Just like a strongly branded website, an enthusiastic social media presence also acts as a landing point for potential patients to get to know what you’re all about. Profiles on <strong>Facebook</strong>, <strong>Twitter</strong>, <strong>Instagram</strong>, and <strong>LinkedIn </strong>are essential to building the trust of your audience. The most engaging accounts are those that are most personable: make sure to reference the everyday when posting, and don’t forget to spread positivity whenever you can (nobody likes bad news).</p><p>Our top tip:</p><p>Check out these articles from our archives for more advice on marketing your clinical trial for the digital age.</p><ul><li><a href="https://www.citruslabs.com/post/2020/01/16/fear-of-the-doctor-how-to-destigmatize-clinical-trials">Marketing a trial while tackling the stigma of clinical research</a></li><li><a href="https://www.citruslabs.com/post/why-should-i-care-the-importance-of-patient-engagement">‘Why should I care?’: appealing to the individual</a></li><li><a href="https://www.citruslabs.com/post/patient-recruitment-the-lifeline-for-research-right-now">The importance of trial recruitment companies in gaining patient trust</a></li></ul><h3>4. Patient recruitment companies</h3><p>For many, hiring patient recruitment specialists seems impossible; and most of the time, let’s face it, this impossibility comes down to monetary reasons. However, what many fail to remember is that time is money, and the key thing that PRCs will certainly save you is time. According to <a href="https://www.centerwatch.com/articles/24543-recruitment-rates-rising-but-retention-rates-fall-according-to-new-study">a study</a> by the Tufts Center for the Study of Drug Development (CSDD), time is a necessity for researchers right now as recruitment rates seem to be on the rise but retention rates are failing to keep up. The study states that, of the trials carried out by four of the top-20 biopharma companies and one CRO involved, <strong>actual enrollment exceeded planned enrollment in 2019 by 113%</strong>; yet, sadly, this was only a temporary victory as the same<strong> trials reported dropout rate rising to 19.1%</strong> — up from 15.3% reported in 2012. This worrying trend, in turn, suggests that researchers should now be investing more of their own time in keeping patients happy.</p><p>The issue with this is that it is too simplistic to suggest that researchers can easily juggle recruitment and retention on their own. Given the current climate, it may be wise for research operators to invest in more secure and reliable methods of recruitment — sparing them vital time to plan and implement patient-centric care metrics. This is, of course, where patient recruitment companies come in.</p><p>Not that we are biased, but if we were to recommend anyone company for the job it would have to be Citruslabs. Linked to<strong> our #1 health app in 17 countries</strong>, Mindmate, our patient-recruitment dashboard directly connects researchers to <strong>over 3 million registered patients</strong>. Now, we would say that other models are available — but this would be a lie. In fact, our easy-to-use dashboard is <strong>the first-of-its-kind for the market</strong>; offering researchers a unique insight into patients’ wants and needs via industry-leading technology. The future of patient recruitment starts here.</p><p>Still a little unsure? Check out what our customers have to say about us <a href="https://www.citruslabs.com/casestudies">here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c425a1192343" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why telemedicine is the future of migraine research]]></title>
            <link>https://medium.com/@citruslabs/why-telemedicine-is-the-future-of-migraine-research-7912db088af9?source=rss-55e5d328832d------2</link>
            <guid isPermaLink="false">https://medium.com/p/7912db088af9</guid>
            <category><![CDATA[migraine-research]]></category>
            <category><![CDATA[patient-recruitment]]></category>
            <category><![CDATA[patient-engagement]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Citruslabs]]></dc:creator>
            <pubDate>Thu, 25 Jun 2020 00:53:30 GMT</pubDate>
            <atom:updated>2020-06-25T00:53:30.393Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dsCLua-wdb1qDvvAfz8MmA.jpeg" /></figure><p>With the launch of Theranica Bioelectronics’ initiative for wider distribution of their product, Nervivio, via UpStart’s telemedicine platform, it is certainly beneficial for the industry to consider the impact of telemedicine on the future of migraine research. Affecting around <strong>38 million people in the United States</strong> and<strong> about 10% of people worldwide</strong>, migraines are among the most prevalent diseases in the world today. While a change in lifestyle, such as a change in diet, exercise, and/or stress management, cannot be overlooked in migraine prevention and treatment, the need for alternative methods of intervention is strong.</p><p>As the average patient looks to spend less time in waiting rooms and more time monitoring their own treatments, we take a look at <strong>the current issues facing the industry today</strong> and how <strong>telemedicine strategies</strong> may be able to resolve them.</p><h3>Where are the problems?</h3><p>The fact is that, right now, medical professionals in the US are overburdened; an article by The New York Times reveals ‘patients are treated like widgets, and doctors and nurses are treated like assembly-line employees’. The same report finds that there are actually more administrators than doctors available to respond to patient needs, with <strong>the current ratio between staff at 10:1</strong>. This needs to change if researchers hope to give patients a positive and customized experience.</p><p>A <a href="https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/highlights.pdf">study</a> by IQVIA also estimates that the US spends around <strong>$2.9 trillion on healthcare every year</strong>, which is more than any other nation per annum. Yet, it is also assumed that around <strong>$200 billion of these costs could be avoided</strong>. Some of these unnecessary costs cover travel expenses for appointments and medication non-adherence — both of which can be easily avoided if researchers employ a series of telemedicine strategies.</p><h3>How does telemedicine work?</h3><p>The key benefit to telemedicine is <strong>an increase in the quality of patient care.</strong> As patients can be digitally linked to researchers, candidates can now voice any worries or concerns via a technological platform — with some platforms allowing 24/7 modes of communication. Today, there are around <strong>4.57 billion active internet users</strong> as of April 2020; meaning that the Western world is more connected than ever before. This, in turn, opens up opportunity for the research industry to take advantage of.</p><p>As in-person medical care is an increasing challenge for many, telemedicine will now save a vast amount of patients a trip to the pharmacy. A<a href="https://americanmigrainefoundation.org/resource-library/covid-19-migraine/"> report</a> published by <strong>the American Migraine Foundation</strong> backed up these claims by recommending telemedicine as an alternative to traditional methodologies, proving this change to be especially beneficial under social-distancing regulation. While traditional medications are still recommended, the use of telemedicine will be essential for providing alternatives that we are now seeing emerge from the industry, with Nervivio being only the first in a long line of industry-reforming solutions.</p><p>Here at Citruslabs, we are dedicated to keeping you up-to-date on the latest clinical trial news and developments. As a company, we have a wealth of experience in the field; with the success of <strong>our #1 health app</strong>, <a href="https://www.mindmate-app.com/">Mindmate</a>, and a trial database with <strong>over 3 million patients on record</strong>. Not only this, we are proud to offer <strong>all COVID-19 clinical trials free access</strong> to our patient-recruitment dashboard.</p><p><strong>Interested in finding out more? Get in touch with one of our team</strong><a href="https://www.citruslabs.com/contact"><strong> here</strong></a><strong>, and check out our</strong><a href="https://www.citruslabs.com/blog"><strong> archives</strong></a><strong> for all our top tips and tricks on running a successful clinical trial in today’s constantly changing industry.</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7912db088af9" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>